ChromaDex Corporation Stock News

ChromaDex (CDXC) said a phase 1 trial showed that its Niagen ingredient supplementation significantly increased brain nicotinamide adenine dinucleotide ((NAD)) levels, and resulted…

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed. March 9, 2022 at 4:30 p.m. ET to discuss its financial results for

ChromaDex (CDXC) is trading ~6% higher in pre-market on Wednesday after the company announced the issuance of a new U.S

ChromaDex (CDXC) is trading ~2.5% higher in the pre-market after announcing a supply agreement with Designs for Health to offer new products formulated with Niagen.Accordingly, Designs

ChromaDex Corp (NASDAQ:CDXC) has announced a supply agreement with Designs for Health, a U.S.-based manufacturer of premium dietary supplements for healthcare practitioners (HCPs).  ChromaDex's p

Chromadex Corp (CDXC) shares closed today at 1.7% above its 52 week low of $2.96, giving the company a market cap of $205M. The stock is currently down 19.5% year-to-date, down 35.5% over the past 12 months, and up 2.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.3%. Trading Activity Trading volume this week was 20.7% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at -0.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Materials industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 489.7% The company's stock price performance over the past 12 months lags the peer average by 37.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Chromadex Corp (CDXC) shares closed today at 1.7% above its 52 week low of $2.96, giving the company a market cap of $205M. The stock is currently down 19.5% year-to-date, down 35.4% over the past 12 months, and up 0.7% over the past five years. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.3%. Trading Activity Trading volume this week was 21.2% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at -0.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Materials industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 489.7% The company's stock price performance over the past 12 months lags the peer average by 33.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Chromadex Corp (CDXC) shares closed today at 0.3% above its 52 week low of $3.30, giving the company a market cap of $226M. The stock is currently down 11.5% year-to-date, down 31.5% over the past 12 months, and down 9.8% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 86.5% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at -0.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Materials industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 956.6% The company's stock price performance over the past 12 months lags the peer average by 22.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Equities analysts expect that ChromaDex Co. (NASDAQ:CDXC) will announce $18.53 million in sales for the current fiscal quarter, Zacks reports. Three analysts have made estimates for ChromaDexs earnings, with the highest sales estimate coming in at $19.00 million and the lowest estimate coming in at $17.86 million. ChromaDex reported sales of $15.45 million during the []

Equities analysts expect that ChromaDex Co. (NASDAQ:CDXC) will report sales of $18.53 million for the current fiscal quarter, Zacks reports. Three analysts have made estimates for ChromaDexs earnings, with the lowest sales estimate coming in at $17.86 million and the highest estimate coming in at $19.00 million. ChromaDex reported sales of $15.45 million during the []

Goldman Sachs Group Inc. decreased its position in ChromaDex Co. (NASDAQ:CDXC) by 18.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 381,122 shares of the companys stock after selling 86,191 shares during the quarter. Goldman Sachs Group Inc. owned 0.56% of ChromaDex worth []

On Sept. 21, 2021, the U.S. District Court for the District of Delaware granted Elysiums motion for summary judgment that two ChromaDex formulation patents were directed to patent-ineligible subject matter under 35 U.S.C. § 101. ChromaDex, Inc. et al. v. Elysium Health, Inc., Civil Action No. 18-1434-CFC-JLH, 2021 WL 4286527, at *1 (D. Del. Sep. 21, 2021) (ChromaDex). The two ChromaDex patents, U.S. Patent Nos. 8,197,807 and 8,383,086, concerned compositions and pharmaceutical formulations of By: Kramer Levin Naftalis & Frankel LLP

ChromaDex Corporation (CDXC) CEO Rob Fried on Q3 2021 Results - Earnings Call Transcript

ChromaDex (NASDAQ:CDXC) reported its Q3 earnings results on Wednesday, November 3, 2021 at 04:02 PM. Here's what investors need to know about the announcement.

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ataxia--ChromaDex Corp. (NASDAQ:CDXC) today announced promising findings from a first-of-its-kind clinical study published in the peer-reviewed journal, Movemen